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Introduction
Venous thromboembolism (VTE) encompass both deep 
vein thrombosis (DVT) and pulmonary embolism (PE), 
representing in Western countries the third most frequent 
cardiovascular disease (after ACS and Stroke), and the 
third most common cause of hospital-related death. 
Every year, up to one million individuals are affected by 
DVT/PE, with a similar incidence in the USA and Europe 
(0.96–3.0 per 1,000 and 0.75–2.69 per 1,000, respectively) (1). 
It has been estimated that every year the number of 
VTE-related deaths is between 100,000 and 296,000 in the 
USA and 370,000 in Europe (2). Moreover, non-lethal PE 
may lead to chronic disease and disability (3). However, 
the exact incidence of VTE is unknown and difficult to 
determine because PE may remain asymptomatic and is 
often diagnosed after incidental finding. In fact, data are 
likely to be substantially higher since silent PE develops 
in up to 50% of patients with DVT and may remain 
undiagnosed for long (2). The severity of acute PE is assessed 
according to in-hospital or 30-day mortality in low-risk (LR), 
intermediate-risk (or submassive) and high-risk (or massive) 
acute PE. Among these, 7 out of 10 patients suffer from LR-
PE and have preserved right ventricular function and absence 
of biomarkers of cardiovascular damage. Signs of right heart 
dysfunction and/or presence of biomarkers of cardiovascular 
damage, without persisting hypotension or shock, characterize 
the submassive EP form. Lastly, acute massive PE is the most 
severe form, characterized by signs of compromised respiratory 
or haemodynamic condition, with signs and symptoms of 
shock and a mortality rate that exceeds 20% irrespective of 
treatment. Early diagnosis is extremely important in massive 
PE since 70% of patients die within 1 hour from the onset of 
clinical signs of the disease because of a dramatic reduction 
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of cardiac output finally leading to cerebrovascular 
complications and multiorgan failure (4).
Pathophysiology 
PE compromises both gas exchange and circulation. In 
fact, both mechanical obstruction and PE-associated 
vasoconstriction, which is mediated by increased release 
of thromboxane A2 and serotonin, may increase RV 
afterload (5). Of note, pulmonary vascular resistance arises 
dramatically with the increasing of the clot burden. As a 
result, RV wall is stretched, triggering a compensatory 
activation of the neurohumoral axis that exerts inotropic 
and chronotropic effects. Unfortunately, this temporary 
adaptive mechanism increases the trophic demand of 
the myocardium and may lead to RV bowing to the 
interventricular septum, a phenomenon that reduces LV 
systemic output, further exacerbating haemodynamic 
instability and hypotension (6). These combined effects, 
lead to a drop of coronary perfusion and ischaemic 
RV suffering. The consequent reduction of RV output 
compromises LV pre-load and systemic blood pressure, 
setting a pathophysiologic degenerative loop that may lead 
to cardiogenic shock, which is the primary cause of death in 
severe PE. Acute massive PE is the most severe form, with 
mortality rates exceeding 20% irrespective of treatment. 
In fact, acute massive PE can ultimately result in sudden 
death secondary to massive obstruction of the pulmonary 
bed (approximately 10% of PE cases) (7). In detail, acute 
massive PE is characterized by hemodynamic instability, 
persistent hypotension, and cardiogenic shock. Moreover, 
acute massive PE causes acute cor pulmonale, a condition 
consistent with acute RV dilation and failure, hypokinesis, 
tachycardia, the presence of gallop rhythm, acute tricuspid 
regurgitation and signs of increased central venous pressure. 
Diagnosis
Acute PE is often associated with poorly predictive signs e.g., 
chest pain, dyspnea, haemoptysis and, infrequently, syncope 
and arterial hypotension. Despite the low specificity and 
sensitivity of these, the use of largely accepted prediction 
rules and appropriate straightforward diagnostic algorithms 
may help the clinician in the evaluation of the likeliness of 
an ongoing PE. These principles are extensively revised in 
the 2014 ESC guidelines for the diagnosis and management 
Figure 1 PE diagnostic algorithm according to 2014 ESC guidelines. PE, pulmonary embolism. PE, pulmonary embolism; CTA, computed 
tomography angiography; HypoTN, hypotension.
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of acute PE (8) and are hereafter summarized.
First, the clinician should classify patients with suspected 
PE into pre-test clinical categories that correspond to the 
probability that the ongoing pathology is actually confirmed 
to be acute PE. The Well’s (9) and revised Geneva (10) 
rules are useful tools that have been extensively validated 
and simplified to encourage their clinical routine utilization 
(11,12). These rules can provide a two-level score {PE 
unlikely [prevalence (p.) ≈12%] – PE likely} or three-level 
score [low-probability (LP: p. ≈10%), medium probability 
(MP: p. ≈30%) and high-probability (HP: p. ≈65%)]. 
Clearly, severely ill patients suffering from systemic shock 
or hypotension undergo a more rapid diagnostic algorithm 
(Figure 1) that is performed on urgently or emergently.
CT angiography (CTA) has become the method of 
choice for the diagnosis of PE, with a sensibility for a multi-
detector device of 83% and a specificity of 96% (13). In fact, 
CTA allows a highly spatially and temporally resolved 
visualization of the arteries down to at least the segmental 
level (14). However, limited CTA availability and the 
intrinsic invasiveness of this technique may require 
different diagnostic tools to be used. Echocardiography may 
represent a useful non-invasive tool for haemodynamically 
unstable patients, detecting signs of RV overload and, 
eventually, direct imaging of the thromboemboli. Since RV 
overload is an aspecific sign, echocardiography should be 
used only to exclude PE for patients with haemodynamic 
instability. Moreover, in haemodynamically unstable 
patients without RV overload, echocardiography may reveal 
other possible causes of shock, e.g., heart tamponade, 
valvular dysfunction, aortic dissection, hypovolemia and left 
ventricular dysfunction. Conversely, if a further differential 
diagnosis is not immediately feasible and/or the patient 
is not stabilized, echocardiography may justify the use of 
emergency reperfusion (15). Due to its poor predictive value, 
echocardiography is not recommended for haemodynamically 
stable normotensive patients, which may undergo CTA in 
the case they are stratified as ‘high-probability PE’. Medium- 
and low-probability patients are tested for D-dimer, which 
is abundantly formed in case of concomitant activation of 
coagulation and fibrinolysis. Most ELISA or ELISA-derived 
D-dimer tests have a 95% sensibility and can, therefore, be 
used to exclude PE. On the contrary, a positive result should 
be further confirmed by CTA.
Management
Restoration of systemic pressure is necessary both for end-
organ perfusion and to reverse RV ischemia. However, only 
small volumes (i.e., 500 mL) of fluid should be perfused to 
avoid deleterious compensatory overstretch responses that 
may further compromise RV function (16). In combination, 
a vasodilator such as norepinephrine and epinephrine are 
good choices to restore systemic blood pressure considering 
their positive inotropic effect. Once systemic blood pressure 
is restored, adding dobutamine can also exert beneficial 
effects on circulation. In fact, dobutamine can restore 
cardiac output and RV-PA coupling (17). Nevertheless, 
systemic vasodilation has been criticized for its lack of 
specificity. To directly improve lung perfusion and gas 
exchange, inhalation of nitric oxide has been proposed 
and triad in several trials (18,19). Respiratory failure 
caused by PE is best treated with rapid clot reduction (i.e., 
thrombolytics) without intubation and positive pressure 
ventilation. However, patients that undergo pre-surgical 
anesthesia or that show frank respiratory collapse may 
require intubation. Care should be paid to avoid that the 
positive intrathoracic pressure may worsen venous return. 
Smoothening of the transition to ventilation to a tidal 
volume not exceeding the 6–8 cc/kg lean body weight range 
may preserve the fragile preload-sensitive haemodynamic of 
RV failure (20).
To relieve obstruction and quickly restore blood flow 
in the pulmonary circulation, several options are available, 
including thrombolysis, percutaneous embolectomy, and 
surgical pulmonary embolectomy. The traditional treatment 
for PE consisted of anticoagulation with heparin therapy 
and watchful waiting, an approach that can be safely applied 
in most cases of stable PE. Unstable patients that require 
anticoagulation should be treated with unfractionated 
heparin (UFH), since this form has a short half-life and can 
be easily monitored (21). On the other hand, low molecular 
weight heparin (LMWH) should be preferred routinely, 
since it has a lower risk of inducing major bleeding and 
heparin-induced thrombocytopenia (22,23). Beside 
parenteral anticoagulation, vitamin K antagonists (VKA) 
should be administrated as soon as possible (24). However, 
non-vitamin K oral anticoagulants (NOACs), including 
rivaroxaban, apixaban, dabigatran, and edoxaban, showed 
to be non-inferior to traditional anticoagulant therapy 
and are associated with reduced bleeding risk and VTE 
recurrence (25). 
Nevertheless, hemodynamic instability and evidence 
of RV failure may require more rapid intervention, such 
as thrombolysis, catheter-based therapies and/or surgical 
embolectomy. In fact, the early resolution of the obstruction 
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in the pulmonary circulation immediately improves the 
patient’s hemodynamics, with a reduction in RV preload 
and resistance. Thrombolysis within the first week from 
the clinical onset of the symptoms and, best, within 
48 hours was proved to be beneficial for the 90% of 
patients (26). Possible major complications include several 
forms of life-threatening bleeding and hemodynamic 
deterioration. Interestingly, the use of catheter-based 
technologies mitigates the intrinsic bleeding risk associated 
with systemic thrombolysis. A number of interventional 
opt ions  are  ava i lab le  for  pat ients  wi th  absolute 
contraindication to thrombolysis, including rheolytic 
thrombectomy with hydrodynamic catheter devices, 
rotational thrombectomy, suction thrombectomy and 
traditional thrombus fragmentation with pigtail or balloon 
catheter (27). Conversely, catheter-directed thrombolysis 
or pharmaco-mechanical thrombolysis are the preferred 
approaches for patients without absolute contraindications. 
In fact, local delivery may help to reduce the dosing and 
time of the treatment as well as the side effects, while 
improving its outcome (28). Moreover, augmented 
thrombolysis is achieved using catheter-based ultrasonic 
devices (e.g., EkoSOnic Endovascular System), which 
mechanically destroy the fibrin strands, in combination with 
the local infusion of the chosen fibrinolytic agent.
However, in one hand, thrombolysis and catheter 
thromboembolectomy can rapidly re-establish hemodynamic 
stability, but, on the other hand, these treatments may cause 
distal fragment embolization and hemorrhages. 
Surgical  pulmonary embolectomy is  an option 
recommended in cases of high risk and cardiogenic shock, 
massive PE patients who cannot receive fibrinolysis, or 
remain unstable after its administration, submassive PE 
patients for whom thrombolysis is contraindicated or have 
failed and patients with right heart thrombi located close or 
straddling through a patent foramen ovale (29).
Traditionally, pharmacological options were preferred 
to surgical pulmonary embolectomy (SPE) because of 
the higher mortality rate and invasiveness of the latter. In 
detail, this approach had mortality rates ranging from 
16% to 64% (30). Peri- and post-operative mortality 
has progressively decreased over the time, despite the 
ongoing use of pulmonary embolectomy as the last choice 
in very high-risk patients. The improvement of the 
surgical outcome generated new interest for pulmonary 
embolectomy as a viable treatment option in acute massive 
pulmonary embolism (AMPE) and resulted in an extension 
of the eligibility criteria for surgical embolectomy to 
those who are hemodynamically stable but show signs of 
impending right ventricular (RV) failure. In fact, several 
recent reports indicate that early mortality rates after 
surgical embolectomy have improved to 6–29% (31): 
Takahashi and al. reported a 12.5% in-hospital mortality 
rate for 24 patients undergoing embolectomy (32); 
Leacche et al. reported a series of 47 patients undergoing 
embolectomy with 6% of peri operative mortality rate (30). 
Other studies compared surgical versus medical therapy: 
e.g., Greelish et al. (33) recorded low mortality in 15 
patients treated with surgical embolectomy (47% of them 
were unstable at presentation) compared with 88 patients 
undergoing medical treatment (unstable hemodynamic in 
8% of them at presentation). Early mortality was almost 
equivalent (surgery 13% vs. medical 17%) but late mortality 
was lower at follow-up in surgical groups. A recent meta-
analysis (34) shows the outcomes in 56 studies from 1965 to 
2015, involving 1,579 patients who underwent 1,590 SPE 
operations. The authors highlight an in-hospital all-cause 
mortality of 26.3% and a long-term all-cause mortality rate 
of 6.5 deaths per 100 person-year. Among these patients, 
1/3 had cardiac arrest before surgery, and 1/3 of operations 
required preoperative ECMO support. This study also 
shows how In-hospital mortality rates have fallen over years 
for patients undergoing SPE, particularly in centers where a 
great volume of SPEs is performed. These results may also 
reflect a better patient stratification, more rapid diagnostic 
pathways and protocols, and improved perioperative care. 
Surgical technique
Before the advent of CPB, pulmonary embolectomy was 
performed under occlusion of the vena cava, with a quick 
incision in the pulmonary trunk, then removal of the 
embolus, and suturing of the pulmonary trunk. Nowadays, 
the surgical technique employs normothermic CPB using 
bicaval cannulation and aortic perfusion, but cardiac arrest 
is indeed not mandatory. In past years, deep hypothermic 
circulatory arrest has been widely used, but today this 
method is adopted only in specific cases, e.g., for the 
optimization of the surgical view in complete embolectomy 
in patients suffering from chronic thromboembolic 
pulmonary hypertension (35). 
In the standard technique, after systemic anticoagulation 
is administrated, median sternotomy is performed and 
CPB is instituted. Then, the venae cavae are snared and 
the pulmonary trunk is incised in the proximity of the 
pulmonary valve. The location of the thrombus determines 
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the extension and shape of the cut. In details, left trunk 
arteriotomy is usually performed in a hockey-stick fashion, 
while right pulmonary artery is incised between the 
aorta and the superior vena cava. The extraction of large 
thromboemboli in the proximal pulmonary artery may 
be facilitated by the insertion from the pulmonary trunk 
of forceps and a suction tube. However, the applicability 
of this extraction procedure is limited to directly visible 
thromboemboli at the level of the segmental pulmonary 
arteries (36). Many surgical techniques of thrombus 
extraction have been described aiming to refine the 
procedure at any point, e.g., setting minimally invasive 
alternative to conventional sternotomy, which has always 
been a significant barrier to the broad adoption of the 
surgical approach (37). 
The opening of the bilateral pleura and peripheral clot 
extrusion through manual compression of the lungs have 
also been used. However, attention must be paid with 
patients treated with heparin to avoid mechanical injury of 
the arterial walls and lung parenchyma, which may cause 
endobronchial bleeding. In fact, squeezing of the lung may 
trigger critical lung bleeding in patients on thrombolytic 
therapy, which often leads the patient to death. Recently, 
Fukuda et al. (38) have reported that massive hemorrhage 
in patients under preoperative thrombolytic therapy may 
be managed infusing fresh frozen plasma and platelet 
precipitate. This procedure should be coupled with blocking 
of the involved bronchus with a balloon catheter in cases 
of arterial injury. Lastly, heparin should be reversed after 
the weaning of the CPB, which is often difficult to perform 
due to hypoxia. Interestingly, in a surgical scenario in which 
the right atrium is directly inspected for suspected clots, a 
sophisticated and original maneuver has been described by 
Zarrabi et al. (39). In details, a septal incision through the 
fossa ovalis is performed to get access to the left atrium. 
Then, the surgeon sequentially inserts into each pulmonary 
vein a cannula connected to the pump oxygenator and 
flushes for 60–80 seconds with a mean pressure of 15–17 
mmHg. This pressure flushes retrogradely through the 
pulmonary veins clot and debris, which are then removed 
through pulmonary arteriotomy. The procedure lasts 5 
minutes and, typically, it is possible to directly suture the 
pulmonary arteriotomy. Nevertheless, a bovine pericardial 
patch may be used in those patients whose pulmonary artery 
is particularly thin and fragile. When these efficient, time-
saving procedures are operated, the patient can be weaned 
from CPB without any variation from the standard method. 
Extracorporeal membrane oxygenation
Mechanical cardiopulmonary support is traditionally used 
for cardiothoracic surgery whenever cardiopulmonary 
bypass is temporarily required to facilitate circulation 
and oxygenation during the operation. Prolonged 
cardiopulmonary support is also used outside of the 
operating room in the intensive care unit to provide 
respiratory and/or hemodynamic assistance, a practice 
that is called ‘extracorporeal membrane oxygenation’ 
(ECMO). Two forms of ECMO are primarily utilized in 
the clinical practice: veno-arterial (VA) and veno-venous 
(VV). Both these forms can provide respiratory support 
by oxygenating and removing carbon dioxide (CO2) from 
the blood, but only VA ECMO provides hemodynamic 
support and is thus adopted in patients with cardiogenic 
shock. It is worth mentioning a third form of ECMO, 
called arterio-venous (AV) ECMO, which is limited to cases 
of poor blood flow to remove CO2. In general, ECMO 
should be considered as a bridge to recovery, while other 
therapeutic interventions are being performed and/or as an 
external support to facilitate the natural healing process. 
In fact, ECMO is generally indicated for patients suffering 
from any respiratory or cardiac failure that is potentially 
reversible when conventional therapies have failed (40). 
Clinical scenarios in which ECMO may be used include 
severe hypoxemic or hypercapnic respiratory failure despite 
ventilator optimization, cardiogenic shock refractory to 
treatment, and bridge to cardiac or lung transplantation. 
ECMO in any case in which there is a contraindication 
to anticoagulation (i.e., recent surgery, high bleeding risk, 
recent hemorrhagic stroke, etc.) since ECMO requires full 
heparinization to work without blocking the system. Other 
contraindications may include a poor baseline functional 
status, advanced age, neurologic dysfunction, severe obesity, 
unrecoverable condition, not a candidate for transplant or 
ventricular assist device, chronic organ dysfunction such 
as emphysema, cirrhosis, or renal failure, and prolonged 
cardiopulmonary resuscitation (CPR) without adequate 
perfusion of end organs. 
In the setting of massive pulmonary embolism and 
hemodynamic failure, cardio-pulmonary support should be 
used according to the following principles: 
(I) Reduction in PVR;
(II) Bridge to systemic or catheter-based thrombolysis, 
or surgery or catheter embolectomy;
(III) RV preload optimizations;
(IV) Restoration of systemic blood pressure and RV 
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coronary perfusion by optimizing afterload 
(vasoconstriction);
(V) Improvement in RV function;
Although most patients can be weaned from CPB after 
surgical pulmonary embolectomy, some patients with 
right ventricular failure need post-operative heart-lung 
assist. In massive PE, ECMO is an important therapeutic 
option for the hemodynamic stabilization of the patient 
before pulmonary embolectomy. However, the most severe 
complication is brain damage from prolonged hypoxemia 
and hypotension before surgery. Brain damage after 
pulmonary embolectomy is a critical concern, particularly 
after the long period of circulatory arrest that is required 
to perform the intervention. Rapid decision making about 
ECMO treatment is crucial to saving critically ill patients. 
Another valuable option for right ventricle assistance 
is the Impella RP device (41), a 9-Fr catheter designed to 
reach the right atrium through a standard femoral vein 
insertion. This pump draws blood from an inlet that sits in 
the IVC and expels it directly into the pulmonary artery. 
This device can pump up to 4.0 L of blood and it has been 
studied and approved for the treatment of right heart failure 
and is based on the same technology of its predecessors 
(i.e., Impella CP and 5.0). These are percutaneously placed 
and augment left ventricular cardiac output in case of high-
risk percutaneous coronary intervention and cardiogenic 
shock. To date, this device has not been yet approved for 
RV failure in the setting of PE, but it’s possible that it may 
have a role in future since it has been shown that both stable 
and unstable patients with PE who undergo pulmonary 
embolectomy may benefit from an IVC filter (42).
Conclusions
The outcomes of pulmonary embolism are highly dependent 
on the presence or absence of circulatory collapse, and very 
advanced cardiac condition as cardiac arrest and external 
massage. A multidisciplinary approach with rapid non-
invasive diagnostics, proper risk stratification and availability 
of immediate surgical treatment are crucial to achieving 
superior results. Since many studies highlight higher in-
hospital mortality among patients with preoperative cardiac 
arrest, SPE should be considered for patients before the 
development of advanced hemodynamic instability, and 
before progression to cardiogenic shock. In long-term 
studies, there is evidence that long-term cardiovascular 
and non-cardiovascular mortality rates are similar. Of note, 
PE is often related with other pathologies, and the patient 
survival depends often on the predisposing disease rather 
than the PE itself, as long as PE is properly treated. The 
increasing availability of ECMO and the increasing efforts 
for the standardization of this delicate surgical procedure 
has dramatically improved the post-operative outcome 
of SPE, suggesting that surgery is a valuable option 
in the treatment of PE with severe RV dysfunction or 
hemodynamic instability. There is a need to reeducate in the 
future, both medical and surgical trainees should be formed 
and/or updated on the role of SPE in the treatment of acute 
PE, particularly in those centers in which is available a 
surgical expertise in performing SPE. However, further new 
studies reporting the outcomes of pulmonary embolectomy 
are crucial to improve decision-making about the treatment 
protocols for AMPE and to increase awareness of surgical 
management options and coordination among the members 
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